Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 7/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.30 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303768 | 0.93 | GHSR (0.34) | GHSRSMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL13321376 | 0.92 | GHSR (0.37) | GHSRSMN1; SMN2MEN1KMT2ACHRM2 | |
| SCHEMBL12238987 | 0.87 | YAP1 (0.39) | MEN1KMT2AKCNH2 | |
| SCHEMBL12824794 | 0.86 | ME2 (0.38) | GHSRMEN1KMT2A | |
| SCHEMBL14553783 | 0.86 | GHSR (0.33) | GHSRSMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL1684602 | 0.85 | SCNN1A (0.36) | GHSRSMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL2142417 | 0.85 | SCNN1A (0.37) | GHSRMEN1KMT2ACHRM2PANK3 | |
| SCHEMBL12238991 | 0.84 | MEN1 (0.39) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL12215593 | 0.84 | GHSR (0.36) | GHSRSMN1; SMN2HPGDNPSR1HSD17B10 | |
| SCHEMBL12239812 | 0.83 | NPY5R (0.33) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | GHSR 1249/4885SMN1; SMN2 1712/4885MEN1 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.